Munoz legislation allows substitution of biologics for biosimilar prescriptions

SPRINGFIELD – Today, legislation sponsored by State Senator Tony Munoz (D-Chicago) that would allow pharmacists to substitute a prescription for a biological product with a biosimilar product was approved by the Senate.

A biologic is an original medical product that is manufactured by an innovator. A biosimilar is an approved version of that product that can be made available after the original product patent expires. As with name-brand prescriptions and generics, pricing for the latter is usually more affordable.

“This is important at a time when we’re searching for ways to upgrade our healthcare system,” Munoz said. “Allowing the use of biosimilar products as substitutions for biologic medicines creates the potential for cost savings and better patient outcomes.”

Senate Bill 455 reflects federal law by creating an abbreviated pathway for the approval of biologics by the federal Food and Drug Administration.

The measure now moves to the House for consideration.

Further Reading: Unleashing The Potential Of Biosimilars